GENE EDITING SOLUTIONS
Delivering the Next Evolution of Healthcare
Recombinetics is a recognized leader in animal gene-editing and associated applied technologies for biomedical research, regenerative medicine and animal agriculture.
We leverage our proprietary gene-editing platform to commercialize and deploy technologies through three subsidiaries that pivotally impact human health and longevity and add value to farm animals.
FACING THE FACTS
people are currently on the U.S. transplant list—83% are waiting for a kidney
human disease research models are currently based on
smallholders raising unproductive animals
Recombinetics has the most experienced and reliable animal gene-editing team on the planet developing solutions through three customer-facing subsidiaries focused on three key areas:
Mayo Clinic Collaboration
Recombinetics has joined forces with the Mayo Clinic in a multi-project, collaborative research and development agreement to advance capabilities to bioengineer human stem cells within swine models. The collaboration is focused on providing better health outcomes for patients by delaying the need for a transplant and reducing other complications including rejection and related cancers.